NCT03514121 2024-11-22
FPA150-001
Five Prime Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
Clinical Trials
4 trialsNCT03694834 2023-11-28
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT04777708 2023-03-24
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT02591654 2022-12-30
MPAK
Columbia University
Phase EARLY_PHASE1 Terminated